Immutep Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immutep Limited (IMMP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immutep Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 10M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Scale: Immutep Limited ranks #224 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Immutep Limited accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMMP Sales vs. its Competitors, Q4 2025
Immutep Limited generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 31.8% for Immutep Limited. Immutep Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Immutep Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immutep Limited | - | - | - | - |
| High-Confidence Competitors (16) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMMP Stock Performance relative to its Competitors
IMMP Stock Performance relative to High-Confidence Competitors
IMMP Stock Performance relative to Similar-Size Competitors
Immutep Limited's Comment on Competition and Industry Peers
Immutep Limited's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| GlaxoSmithKline plc | Named by the company | 85% |
| Incyte Corporation | Named by the company | 85% |
| Regeneron Pharmaceuticals, Inc. | Named by the company | 85% |
| Bicara Therapeutics Inc | Named by the company | 85% |
| AstraZeneca PLC | Named by the company | 85% |
| Eisai Co Ltd. | Named by the company | 85% |
| ImmunityBio, Inc | Named by the company | 85% |
| Nektar Therapeutics | Named by the company | 85% |
| Amgen Inc. | Named by the company | 85% |
| Checkmate Pharmaceuticals, Inc. | Named by the company | 85% |
| Hoffmann-La Roche Ltd. | Named by the company | 85% |
| Innate Immunotherapeutics Ltd. | Named by the company | 85% |
| AbbVie, Inc. | Named by the company | 85% |
| BioLineRx Ltd. | Named by the company | 85% |
| Gilead Sciences Inc. | Named by the company | 85% |
| Immunomedics, Inc. | Named by the company | 85% |
| Oncosec Medical, Inc. | Named by the company | 85% |
| Arcus Biosciences Inc. | Named by the company | 85% |
| Curevac NV | Named by the company | 85% |
| Idera Pharmaceuticals, Inc. | Named by the company | 85% |
| Merck & Co | Named by the company | 85% |
| Aduro Biotech, Inc. | Named by the company | 85% |
| Birdie Biotech, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Immutep Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.